Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Abstract Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen o...
Main Author: | Anand Rotte |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1259-z |
Similar Items
-
Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
by: Yuqian Feng, et al.
Published: (2021-02-01) -
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
by: Kongju Wu, et al.
Published: (2019-10-01) -
Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01) -
Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells
by: Krzysztof Piersiala, et al.
Published: (2022-09-01) -
LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
by: Bai-Wei Zhao, et al.
Published: (2022-10-01)